Serum proteomic profiling reveals that pretreatment complement protein levels are predictive of esophageal cancer patient response to neoadjuvant chemoradiation.

Serum proteomic profiling reveals that pretreatment complement protein levels are predictive of esophageal cancer patient response to neoadjuvant chemoradiation.

Item
http://www.wikidata.org/entity/Q34049835
The mechanisms of radioresistance in esophageal squamous cell carcinoma and current strategies in radiosensitivityCurrent status of predictive biomarkers for neoadjuvant therapy in esophageal cancerMALDI imaging on large-scale tissue microarrays identifies molecular features associated with tumour phenotype in oesophageal cancer.Mass spectrometry-based serum and plasma peptidome profiling for prediction of treatment outcome in patients with solid malignancies.Clinical predictive circulating peptides in rectal cancer patients treated with neoadjuvant chemoradiotherapy.Circulating mRNA Profiling in Esophageal Squamous Cell Carcinoma Identifies FAM84B As A Biomarker In Predicting Pathological Response to Neoadjuvant ChemoradiationProgress in the development of protein biomarkers of oesophageal and gastric cancers.A targeted proteomic strategy for the measurement of oral cancer candidate biomarkers in human saliva.Low miR-187 expression promotes resistance to chemoradiation therapy in vitro and correlates with treatment failure in patients with esophageal adenocarcinoma.Clinical tools to predict outcomes in patients with esophageal cancer treated with definitive chemoradiation: are we there yet?Current Status of Proteomics of Esophageal Carcinoma.Proteomics approach to identify biomarkers for upper gastrointestinal cancer.Serum microRNA-193b as a promising biomarker for prediction of chemoradiation sensitivity in esophageal squamous cell carcinoma patients.Complement in cancer: untangling an intricate relationship.Value of CT-PET after neoadjuvant chemoradiation in the prediction of histological tumour regression, nodal status and survival in oesophageal adenocarcinoma.The Complement C3a Receptor Contributes to Melanoma Tumorigenesis by Inhibiting Neutrophil and CD4+ T Cell Responses.Leukaemia inhibitory factor is associated with treatment resistance in oesophageal adenocarcinoma
P2860

Serum proteomic profiling reveals that pretreatment complement protein levels are predictive of esophageal cancer patient response to neoadjuvant chemoradiation.

Item
http://www.wikidata.org/entity/Q34049835
description
2011 nî lūn-bûn
@nan
2011 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Serum proteomic profiling reve ...... to neoadjuvant chemoradiation.
@ast
Serum proteomic profiling reve ...... to neoadjuvant chemoradiation.
@en
Serum proteomic profiling reve ...... to neoadjuvant chemoradiation.
@nl
type
label
Serum proteomic profiling reve ...... to neoadjuvant chemoradiation.
@ast
Serum proteomic profiling reve ...... to neoadjuvant chemoradiation.
@en
Serum proteomic profiling reve ...... to neoadjuvant chemoradiation.
@nl
prefLabel
Serum proteomic profiling reve ...... to neoadjuvant chemoradiation.
@ast
Serum proteomic profiling reve ...... to neoadjuvant chemoradiation.
@en
Serum proteomic profiling reve ...... to neoadjuvant chemoradiation.
@nl
P1433
P1476
P2093
P304
P31
P356
P407
P433
P478
P50
P577
P698
P921
P356
P1433
P1476
Serum proteomic profiling reve ...... to neoadjuvant chemoradiation
@en
P2093
P304
P31
P356
10.1097/SLA.0B013E31823699F2
P407
P433
P478
P50
P577
P698
P921